Alpelisib vs everolimus after endocrine therapy fails

When hormone receptor positive, HER2-negative metastatic breast cancer grows despite hormone treatment, often after a CDK4/6 inhibitor, two targeted tablets are frequently discussed: alpelisib and everolimus. Both act on the same broad growth pathway inside cancer cells, called PI3K, AKT and mTOR, which helps cancers resist hormone therapy. They work at different points in that pathway, and they are paired with different hormone treatments. Alpelisib blocks PI3K and is taken with fulvestrant injections. It is used only when the cancer carries a PIK3CA mutation, which is found in around four in ten of these cancers. In its main study, it kept PIK3CA-mutated cancers controlled for roughly eleven months on average, compared with under six months for fulvestrant alone. Everolimus blocks mTOR, further down the pathway, and is most often taken with exemestane, an aromatase inhibitor tablet. It does not need a mutation test. In its main study, it roughly doubled the time before the cancer grew compared with exemestane alone. The two have never been compared directly in a trial, and both main studies were done before CDK4/6 inhibitors became standard, so benefits today may be smaller. Their side effects differ: alpelisib is known for high blood sugar and rash, while everolimus is known for mouth sores and lung inflammation. The choice depends on your mutation result, health conditions, earlier treatments, access and personal priorities.

Mutation status comes first

Alpelisib needs a PIK3CA mutation, while everolimus does not.

Different side effect profiles

Blood sugar and rash with alpelisib, mouth sores and lung effects with everolimus.

No head-to-head trial

Comparisons rely on separate studies and clinical judgement.

Both medicines are established options, but comparing them is harder than it looks.

They were never tested against each other

The studies involved different patients, partners and time periods.

Most evidence predates CDK4/6 inhibitors

People treated after a CDK4/6 inhibitor today may gain less than the original studies showed.

Newer options add to the choice

Capivasertib, oral hormone tablets for ESR1 mutations and antibody-drug conjugates are also considered now.

What this page cannot tell you

It cannot say which medicine is best for you. That depends on your tests, health and priorities.

Prevention has made both treatments easier than in their early studies.

On alpelisib

Sugar checks before and during treatment, metformin when needed, and a daily antihistamine in the early weeks reduce the main problems.

On everolimus

An alcohol-free steroid mouthwash used from the first day sharply reduces mouth sores. Report any cough or breathlessness early.

For both

Pauses and dose reductions help many people continue, and a dietitian can support eating well.